de Morgan Stanley VanEck Pharmaceutical ETF PPH Historial de posiciones en acciones
Compró
Mantenido
Vendió
| Trimestre | Valor de mercado | Estado | Núm. de acciones |
Cambio en la participación | Valor operado | Peso en el portafolio | Posición de la cartera | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | USD 112 M | Comprar |
1,028,317
+850,470
| +478% | +USD 88 M | 0.01% | 1471 |
|
|
2026
Q1 | USD 18.5 M | Vender |
177,847
-99,759
| -36% | -USD 10.6 M | ﹤0.01% | 3028 |
|
|
2025
Q4 | USD 28.6 M | Vender |
277,606
-377,981
| -58% | -USD 36.8 M | ﹤0.01% | 2608 |
|
|
2025
Q3 | USD 59.2 M | Comprar |
655,587
+117,189
| +22% | +USD 10.3 M | ﹤0.01% | 1877 |
|
|
2025
Q2 | USD 47.4 M | Comprar |
538,398
+446,997
| +489% | +USD 38.7 M | ﹤0.01% | 1981 |
|
|
2025
Q1 | USD 8.33 M | Vender |
91,401
-10,469
| -10% | -USD 943 k | ﹤0.01% | 3510 |
|
|
2024
Q4 | USD 8.79 M | Comprar |
101,870
+18,327
| +22% | +USD 1.66 M | ﹤0.01% | 3515 |
|
|
2024
Q3 | USD 7.94 M | Comprar |
83,543
+3,483
| +4% | +USD 331 k | ﹤0.01% | 3612 |
|
|
2024
Q2 | USD 7.32 M | Vender |
80,060
-24,577
| -23% | -USD 2.19 M | ﹤0.01% | 3577 |
|
|
2024
Q1 | USD 9.49 M | Comprar |
104,637
+15,709
| +18% | +USD 1.38 M | ﹤0.01% | 3390 |
|
|
2023
Q4 | USD 7.24 M | Vender |
88,928
-6,854
| -7% | -USD 537 k | ﹤0.01% | 3621 |
|
|
2023
Q3 | USD 7.65 M | Comprar |
95,782
+29,067
| +44% | +USD 2.34 M | ﹤0.01% | 3364 |
|
|
2023
Q2 | USD 5.26 M | Vender |
66,715
-35,572
| -35% | -USD 2.78 M | ﹤0.01% | 3738 |
|
|
2023
Q1 | USD 7.94 M | Vender |
102,287
-18,339
| -15% | -USD 1.41 M | ﹤0.01% | 3362 |
|
|
2022
Q4 | USD 9.38 M | Comprar |
120,626
+14,621
| +14% | +USD 1.08 M | ﹤0.01% | 3154 |
|
|
2022
Q3 | USD 7.13 M | Vender |
106,005
-83,234
| -44% | -USD 6.13 M | ﹤0.01% | 3325 |
|
|
2022
Q2 | USD 14.5 M | Comprar |
189,239
+147,769
| +356% | +USD 11.5 M | ﹤0.01% | 2639 |
|
|
2022
Q1 | USD 3.31 M | Comprar |
41,470
+301
| +0.7% | +USD 23 k | ﹤0.01% | 4108 |
|
|
2021
Q4 | USD 3.17 M | Vender |
41,169
-18,646
| -31% | -USD 1.39 M | ﹤0.01% | 4193 |
|
|
2021
Q3 | USD 4.36 M | Comprar |
59,815
+2,147
| +4% | +USD 160 k | ﹤0.01% | 3886 |
|
|
2021
Q2 | USD 4.21 M | Comprar |
57,668
+24,761
| +75% | +USD 1.77 M | ﹤0.01% | 3959 |
|
|
2021
Q1 | USD 2.27 M | Vender |
32,907
-2,808
| -8% | -USD 193 k | ﹤0.01% | 4157 |
|
|
2020
Q4 | USD 2.37 M | Vender |
35,715
-2,531
| -7% | -USD 162 k | ﹤0.01% | 4007 |
|
|
2020
Q3 | USD 2.38 M | Comprar |
38,246
+9,265
| +32% | +USD 586 k | ﹤0.01% | 3503 |
|
|
2020
Q2 | USD 1.8 M | Comprar |
28,981
+1,491
| +5% | +USD 90.2 k | ﹤0.01% | 3685 |
|
|
2020
Q1 | USD 1.5 M | Vender |
27,490
-6,333
| -19% | -USD 390 k | ﹤0.01% | 3618 |
|
|
2019
Q4 | USD 2.17 M | Comprar |
33,823
+9,159
| +37% | +USD 552 k | ﹤0.01% | 3970 |
|
|
2019
Q3 | USD 1.41 M | Comprar |
24,664
+951
| +4% | +USD 54.5 k | ﹤0.01% | 4075 |
|
|
2019
Q2 | USD 1.39 M | Vender |
23,713
-1,382
| -6% | -USD 80 k | ﹤0.01% | 4032 |
|
|
2019
Q1 | USD 1.52 M | Vender |
25,095
-802
| -3% | -USD 47.4 k | ﹤0.01% | 3815 |
|
|
2018
Q4 | USD 1.42 M | Vender |
25,897
-3,928
| -13% | -USD 238 k | ﹤0.01% | 4035 |
|
|
2018
Q3 | USD 1.92 M | Vender |
29,825
-31,895
| -52% | -USD 1.99 M | ﹤0.01% | 4038 |
|
|
2018
Q2 | USD 3.64 M | Comprar |
61,720
+305
| +0.5% | +USD 17.7 k | ﹤0.01% | 3524 |
|
|
2018
Q1 | USD 3.49 M | Vender |
61,415
-30,305
| -33% | -USD 1.81 M | ﹤0.01% | 3435 |
|
|
2017
Q4 | USD 5.44 M | Comprar |
91,720
+21,526
| +31% | +USD 1.23 M | ﹤0.01% | 3025 |
|
|
2017
Q3 | USD 4.06 M | Vender |
70,194
-9,189
| -12% | -USD 522 k | ﹤0.01% | 3190 |
|
|
2017
Q2 | USD 4.69 M | Vender |
79,383
-11,348
| -13% | -USD 642 k | ﹤0.01% | 2913 |
|
|
2017
Q1 | USD 5 M | Vender |
90,731
-4,966
| -5% | -USD 269 k | ﹤0.01% | 2865 |
|
|
2016
Q4 | USD 5.02 M | Comprar |
95,697
+27,320
| +40% | +USD 1.46 M | ﹤0.01% | 2985 |
|
|
2016
Q3 | USD 3.93 M | Vender |
68,377
-113,869
| -62% | -USD 6.83 M | ﹤0.01% | 2905 |
|
|
2016
Q2 | USD 10.7 M | Vender |
182,246
-142,802
| -44% | -USD 8.32 M | ﹤0.01% | 1930 |
|
|
2016
Q1 | USD 18.7 M | Vender |
325,048
-21,954
| -6% | -USD 1.3 M | 0.01% | 1351 |
|
|
2015
Q4 | USD 22.7 M | Vender |
347,002
-86,578
| -20% | -USD 5.59 M | 0.01% | 1306 |
|
|
2015
Q3 | USD 27.3 M | Vender |
433,580
-38,672
| -8% | -USD 2.72 M | 0.01% | 1154 |
|
|
2015
Q2 | USD 33.4 M | Comprar |
472,252
+350,517
| +288% | +USD 25.2 M | 0.01% | 1108 |
|
|
2015
Q1 | USD 8.55 M | Comprar |
121,735
+28,191
| +30% | +USD 1.91 M | ﹤0.01% | 2229 |
|
|
2014
Q4 | USD 6.01 M | Comprar |
93,544
+4,455
| +5% | +USD 284 k | ﹤0.01% | 2548 |
|
|
2014
Q3 | USD 5.66 M | Vender |
89,089
-8,610
| -9% | -USD 533 k | ﹤0.01% | 2543 |
|
|
2014
Q2 | USD 6.06 M | Comprar |
97,699
+2,386
| +3% | +USD 142 k | ﹤0.01% | 2489 |
|
|
2014
Q1 | USD 5.56 M | Vender |
95,313
-100
| -0.1% | -USD 5.66 k | ﹤0.01% | 2492 |
|
|
2013
Q4 | USD 5.07 M | Vender |
95,413
-2,799
| -3% | -USD 142 k | ﹤0.01% | 2552 |
|
|
2013
Q3 | USD 4.7 M | Vender |
98,212
-11,220
| -10% | -USD 532 k | ﹤0.01% | 2482 |
|
|
2013
Q2 | USD 4.98 M | Comprar |
+109,432
| Nuevas | +USD 5.06 M | ﹤0.01% | 2330 |
|
Otros fondos que tienen PPH en su cartera
Posición de Morgan Stanley en PPH: resumen de T2 2026
Morgan Stanley aumentó su participación en VanEck Pharmaceutical ETF (PPH) en 478% durante T2 2026, al comprar aproximadamente USD 88 M y elevar la posición a 1,028,317 acciones con un valor de USD 112 M. La posición representa 0.01% de la cartera y ocupa el puesto #1471.
Morgan Stanley reportó por primera vez una posición en PPH en T2 2013 y la ha mantenido durante 53 trimestres desde entonces. Al cierre de T2 2026, 148 fondos que sigue Wall St. Rank mantienen una posición en PPH.
- Al cierre de T2 2026, Morgan Stanley tenía 1,028,317 acciones de VanEck Pharmaceutical ETF con un valor de USD 112 M.
- Morgan Stanley compró 850,470 acciones de VanEck Pharmaceutical ETF en T2 2026, por un monto estimado de USD 88 M.
- VanEck Pharmaceutical ETF representó 0.01% de la cartera de Morgan Stanley en T2 2026 y fue su posición número 1471.
- Morgan Stanley reportó por primera vez una posición en VanEck Pharmaceutical ETF en T2 2013 y la ha mantenido durante 53 trimestres desde entonces.
- Al cierre de T2 2026, 148 fondos que sigue Wall St. Rank tenían VanEck Pharmaceutical ETF en cartera.
Según el Informe 13F de Morgan Stanley correspondiente a T2 2026, presentado el 13 ago 2026.